Esophagus Cancer
Conditions
Keywords
radiotherapy; cardiotoxicity
Brief summary
Treatment of non-operable esophageal cancers is based on radiochemotherapy, or exclusive radiotherapy. The cardiac toxicity of radiotherapy in the treatment of thoracic tumor localizations is well documented, however, more and more studies are calling for the use of dosimetric parameters related to cardiac sub-structures to be integrated into clinical practice, rather than considering the heart as a whole. With this in mind, the aim of this study is to define the parameters, particularly dosimetric ones linked to cardiac sub-structures, influencing survival in patients treated with exclusive radiotherapy or radiochemotherapy for esophageal cancer.
Detailed description
Treatment of non-operable esophageal cancers is based on radiochemotherapy, or exclusive radiotherapy. The cardiac toxicity of radiotherapy in the treatment of thoracic tumor localizations is well documented, however, more and more studies are calling for the use of dosimetric parameters related to cardiac sub-structures to be integrated into clinical practice, rather than considering the heart as a whole. Although most of these data have been studied in populations with long-term follow-up, such as breast cancer, cardiac toxicity and the reduced survival it entails are also found in diseases such as esophageal cancer. With this in mind, the aim of this study is to define the parameters, particularly dosimetric ones linked to cardiac sub-structures, influencing survival in patients treated with exclusive radiotherapy or radiochemotherapy for esophageal cancer.
Interventions
None listed
Sponsors
University Hospital, Brest
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Age ≥ 18 years * Histologically or cytologically proven esophageal cancer * Localized or locally advanced esophageal cancer treated with radiochemotherapy or exclusive radiotherapy * Tumor dose ≥ 50 Gy * Non-opposition of living patients formulated * Patient affiliated to a social security scheme
Exclusion criteria
* Age \< 18 years * Patient treated with upfront surgery * Tumor dose \< 50 Gy * Other concomitant neoplasia * Metastatic patient * Refusal to participate * Patient under legal protection (guardianship, curatorship, etc...)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Overall survival (OS) | through study completion, an average of 1 year | OS is defined as the time elapsed between inclusion and death, whatever the cause. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| The rate of cardiac events. | through study completion, an average of 1 year | The rate of cardiac events. |
| Response rate. | through study completion, an average of 1 year | Response rate. |
| Progression-free survival (PFS). | through study completion, an average of 1 year | PFS is defined as the time elapsed between inclusion and tumor progression assessed by an expert panel according to RECIST v1.1 criteria, or death from any cause. |
Countries
France
Contacts
Primary ContactVincent BOURBONNE, MD, PhD
Outcome results
None listed